SCHEMBL2592434

SCHEMBL2592434

CSc1ccc(C=C2C=C(CCC(=O)O)c3cc(F)ccc32)cc1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 15/20 0.80
PTGS1 P23219 3/20 0.80
RXRA P19793 3/20 0.57
EGFR P00533 1/20 0.54
CYP1A2 P05177 1/20 0.54
ADORA3 P0DMS8 1/20 0.54
MAPT P10636 1/20 0.54
DRD1 P21728 1/20 0.54
MAPK1 P28482 1/20 0.54
PTGS2 P35354 1/20 0.54
OPRM1 P35372 1/20 0.54
PSEN1 P49768 1/20 0.54
PSEN2 P49810 1/20 0.54
APH1B Q8WW43 1/20 0.54
NCSTN Q92542 1/20 0.54
APH1A Q96BI3 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
PSENEN Q9NZ42 1/20 0.54
CYSLTR1 Q9Y271 1/20 0.54
PTGDR2 Q9Y5Y4 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12181846 1.00 PPARG (0.80) PPARGPTGS1RXRAEGFRCYP1A2
SCHEMBL17092953 1.00 PPARG (0.80) PPARGPTGS1RXRAEGFRCYP1A2
SCHEMBL2582996 0.89 PPARG (1.00) PPARGPTGS1RXRAEGFRCYP1A2
SCHEMBL2582994 0.89 PPARG (1.00) PPARGPTGS1RXRAEGFRCYP1A2
SCHEMBL2697270 0.89 PPARG (1.00) PPARGPTGS1RXRAEGFRCYP1A2
SCHEMBL27914773 0.88 PPARG (0.69) PPARGPTGS1RXRAEGFRCYP1A2
SCHEMBL27914772 0.88 PPARG (0.69) PPARGPTGS1RXRAEGFRCYP1A2
SCHEMBL4548519 0.86 PPARG (1.00) PPARGPTGS1RXRAEGFRCYP1A2
SCHEMBL20158512 0.84 PPARG (0.83) PPARGPTGS1RXRAEGFRCYP1A2
SCHEMBL24453815 0.81 PPARG (0.78) PPARGPTGS1RXRAEGFRCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2571497-A2 METHODS AND COMPOSITIONS RELATED TO A RETINOID RECEPTOR-SELECTIVE PATHWAY Sanford-Burnham Medical Research Institute (US) 2013-03-27 EP claimed
WO-2011140525-A2 METHODS AND COMPOSITIONS RELATED TO A RETINOID RECEPTOR-SELECTIVE PATHWAY SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2011-11-10 WO claimed
CN-107050007-B Methods and compositions relating to retinoid receptor selective pathways 桑福德 - 伯纳姆医学研究所 2020-06-30 CN disclosed
US-10087156-B2 Methods and compositions related to retinoid receptor-selective pathway Sanford Burnham Prebys Medical Discovery Institute (US) 2018-10-02 US disclosed
EP-2571497-B1 METHODS AND COMPOSITIONS RELATED TO A RETINOID RECEPTOR-SELECTIVE PATHWAY SANFORD BURNHAM MED RES INST (US) 2018-09-19 EP disclosed
US-20170313668-A1 METHODS AND COMPOSITIONS RELATED TO RETINOID RECEPTOR-SELECTIVE PATHWAY Sanford Burnham Prebys Medical Discovery Institute 2017-11-02 US disclosed
US-9611235-B2 Methods and compositions related to a retinoid receptor-selective pathway SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2017-04-04 US disclosed
US-20150266842-A1 METHODS AND COMPOSITIONS RELATED TO A RETINOID RECEPTOR-SELECTIVE PATHWAY US ARMY, SECRETARY OF THE ARMY 2015-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170313668-A1 METHODS AND COMPOSITIONS RELATED TO RETINOID RECEPTOR-SELECTIVE PATHWAY RXRG, RXRB, RXRA PPARG 77/4885PTGS1 601/4885RXRA 3/4885
US-10087156-B2 Methods and compositions related to retinoid receptor-selective pathway RXRG, RXRB, RXRA PPARG 77/4885PTGS1 601/4885RXRA 3/4885
US-20150266842-A1 METHODS AND COMPOSITIONS RELATED TO A RETINOID RECEPTOR-SELECTIVE PATHWAY RXRG, RXRB, RXRA PPARG 43/4885PTGS1 217/4885RXRA 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.